SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-070839
Filing Date
2024-03-19
Accepted
2024-03-19 08:46:02
Documents
17
Period of Report
2024-03-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d759882d8k.htm   iXBRL 8-K 36585
2 EX-4.1 d759882dex41.htm EX-4.1 71399
3 EX-10.1 d759882dex101.htm EX-10.1 238973
4 EX-99.1 d759882dex991.htm EX-99.1 29871
8 GRAPHIC g759882g0319113839095.jpg GRAPHIC 4863
  Complete submission text file 0001193125-24-070839.txt   614583

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA elvn-20240319.xsd EX-101.SCH 2886
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE elvn-20240319_lab.xml EX-101.LAB 17978
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elvn-20240319_pre.xml EX-101.PRE 11282
20 EXTRACTED XBRL INSTANCE DOCUMENT d759882d8k_htm.xml XML 3629
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39247 | Film No.: 24761205
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)